EU’s Plans for Regulatory Data Protection ‘Unworkable’
Executive Summary
The European Commission will have a fight on its hands when it comes to the data protection part of its proposals for EU pharma legislative reform.
You may also be interested in...
EFPIA: One Fifth Of Future Products ‘Unviable’ Under EU’s Plans To Modulate Regulatory Data Protection
The European Commission’s pharmaceutical legislation overhaul could result in a loss of 50 expected new products by 2035 and an annual fall in R&D spending of €2bn, the European pharma industry federation EFPIA claims.
Dissent In Parliament As Commission Claims EU Pharma Revision Will Improve Competitiveness and Access
Proposals on regulatory data protection and transferable exclusivity vouchers to encourage antimicrobial R&D have received mixed reactions from the parliament’s rapporteurs for the draft legislation.
Will Shorter EU Regulatory Timelines Mean Unfeasible Joint Clinical Assessment Timelines?
Faster regulatory reviews proposed in the European Commission’s pharmaceutical reform package could impact the EU-level joint clinical assessments that go live from 2025.